New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:43 EDTMRKMerck announces presentation of data evaluating pembrolizumab
Merck announced the first presentation of data evaluating pembrolizumab, Merck’s investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer. In previously-untreated patients, the objective response rate with pembrolizumab as a single-agent was 47% by investigator-assessed, immune-related response criteria and 26% by centrally evaluated RECIST v1.1. In evaluable patients who had measurable disease with one post baseline scan, 80% demonstrated tumor shrinkage as measured by centrally evaluated RECIST criteria. The median duration of response has not been reached, with some patients continuing on treatment with pembrolizumab as monotherapy for at least one year.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use